HomeCompareCRTX vs SBUX

CRTX vs SBUX: Dividend Comparison 2026

CRTX yields 102.56% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CRTX wins by $4.17M in total portfolio value
10 years
CRTX
CRTX
● Live price
102.56%
Share price
$1.95
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.32M
Annual income
$1,481,817.76
Full CRTX calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — CRTX vs SBUX

📍 CRTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCRTXSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CRTX + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CRTX pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CRTX
Annual income on $10K today (after 15% tax)
$8,717.95/yr
After 10yr DRIP, annual income (after tax)
$1,259,545.10/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, CRTX beats the other by $1,203,580.99/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CRTX + SBUX for your $10,000?

CRTX: 50%SBUX: 50%
100% SBUX50/50100% CRTX
Portfolio after 10yr
$2.24M
Annual income
$773,828.94/yr
Blended yield
34.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

CRTX
Analyst Ratings
1
Buy
4
Hold
3
Sell
Consensus: Hold
Altman Z
-4.0
Piotroski
2/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CRTX buys
0
SBUX buys
6
PoliticianChamberTickerTypeAmountDate
Shelley Moore Capito🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-28
Shelley Moore Capito🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-28
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Dan Newhouse🏢 House$SBUX▼ Sell$1,001 - $15,0002025-12-11
Ro Khanna🏢 House$SBUX▼ Sell$15,001 - $50,0002025-10-07
Ro Khanna🏢 House$SBUX▲ Buy$15,001 - $50,0002025-09-29
Ro Khanna🏢 House$SBUX▼ Sell$15,001 - $50,0002025-08-26
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCRTXSBUX
Forward yield102.56%2.75%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$4.32M$157.5K
Annual income after 10y$1,481,817.76$65,840.13
Total dividends collected$3.87M$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusHoldBuy

Year-by-year: CRTX vs SBUX ($10,000, DRIP)

YearCRTX PortfolioCRTX Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$20,956$10,256.41$11,107$407.21+$9.8KCRTX
2$42,511$20,087.62$12,512$626.87+$30.0KCRTX
3$83,570$38,082.81$14,366$978.69+$69.2KCRTX
4$159,386$69,966.82$16,929$1,557.50+$142.5KCRTX
5$295,256$124,712.82$20,658$2,543.80+$274.6KCRTX
6$531,835$215,911.30$26,406$4,302.22+$505.4KCRTX
7$932,535$363,471.12$35,877$7,622.00+$896.7KCRTX
8$1,593,439$595,626.55$52,741$14,352.64+$1.54MCRTX
9$2,656,155$951,175.34$85,676$29,243.03+$2.57MCRTX
10$4,323,904$1,481,817.76$157,513$65,840.13+$4.17MCRTX

CRTX vs SBUX: Complete Analysis 2026

CRTXStock

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Full CRTX Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this CRTX vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CRTX vs SCHDCRTX vs JEPICRTX vs OCRTX vs KOCRTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.